Table 3 Effects of hypertonic saline infusion (3%, 7 ml kg^-1) on U_Na, FE_Na, and u-ENaC _β-CR in 21 patients with essential hypertension and 20 normotensive controls during high and low sodium intake

U _Na (μmol min ^-1 )

HS

Patients

343 (300; 386)§

615 (499; 731)†

700 (581; 819)†

541 (471; 611)†

P = 0.110

Controls

323 (285; 361)§

497 (321; 672)†

499 (357; 642)†

460 (366; 554)†

LS

Patients

91 (57; 125)

254 (168; 340)†

275 (192; 357)†

277 (211; 343)†

P = 0.164

Controls

57 (40; 74)

175 (62; 288)†

191 (99; 282)†

181 (123; 239)†

FE _Na (%)

HS

Patients

2.66 (2.34; 2.98)§

5.10 (4.20; 6.00)†

5.35 (4.46; 6.24)†

4.57 (3.96; 5.19)†

P = 0.030

Controls

2.51 (2.10; 2.92)§

3.73 (2.61; 4.86)†

3.72 (2.76; 4.68)†

3.49 (2.85; 4.14)†

LS

Patients

0.75 (0.49; 1.01)

2.24 (1.55; 2.93)†

2.29 (1.69; 2.90)†

2.28 (1.84; 2.72)†

P = 0.059

Controls

0.49 (0.34; 0.65)

1.34 (0.67; 2.01)†

1.52 (0.90; 2.15)†

1.44 (1.06; 1.82)†

u-EnaC _β-CR (pg μmol ^-1 )

HS

Patients

11.4 (10.2; 12.7)§

10.4 (9.4; 11.3)

10.8 (9.6; 12.1)

11.1 (9.6; 12.6)

P = 0.796

Controls

11.2 (9.9; 12.5)

10.8 (9.7; 12.0)

12.2 (10.7; 13.8)†

11.0 (9.4; 12.6)

LS

Patients

10.4 (9.4; 11.3)

10.7 (9.3; 12.2)

11.5 (10.4; 12.6)†

10.9 (10.0; 11.9)

P = 0.716

Controls

11.5 (9.8; 13.2)

11.2 (10.0; 12.4)

12.4 (11.3; 13.6)†

11.9 (10.2; 13.5)